ArticleInternational journal of chronic obstructive pulmonary disease2025
FFMI: A Pivotal Indicator Bridging Pulmonary, Sleep, and Systemic Factors in COPD-OSA Overlap Patients.
Article in International journal of chronic obstructive pulmonary disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Diagnosis and Management of Overlap Syndrome (COPD-OSA): Evidence, Challenges and Prospects.Nature and science of sleep · 2026Review
- Association between obstructive sleep apnea and the risk of cerebrovascular disease in COPD patients.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Overlap Syndrome (OVS), combining Chronic Obstructive Pulmonary Disease (COPD) and Obstructive Sleep Apnea (OSA), is common yet often unrecognized. This study aims to compare the Fat - Free Mass Index (FFMI) between OVS and simple COPD patients and analyze subgroup differences in OVS for better early identification and severity assessment. Methods: Clinical data of 364 patients (203 in COPD group, 161 in OVS group) were analyzed regarding clinical features, pulmonary function, sleep apnea, etc. The OVS group was divided into low-FFMI and normal-FFMI subgroups (the cutoff value of FFMI < 17kg/m²) for correlation analysis. Results: Statistically significant differences in frequency of acute exacerbations and hospitalizations in the past year, and comorbidities were observed between the COPD group and OVS group (all p < 0.05). The OVS group exhibited significantly lower FEV Conclusion: OVS patients had distinct features like more exacerbations, and lower lung function. The OVS subgroup with different FFMI showed significant differences in lung function and sleep indices. FFMI is closely related to pulmonary function, sleep disorder indices, and exacerbation frequency, suggesting its potential as an important indicator for early OVS identification and severity evaluation despite no significant difference in BMI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.